Clinical trials: Standard Chemotherapy
Non-small Cell Lung Cancer
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small…
- Trial name
- EVIDENCE (NCT02448797)
- Testing
- Icotinib, Chemotherapy
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms (Locally Advanced Non-metastatic)
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas.
- Trial name
- SCALOP-2 (NCT02024009)
- Testing
- nab-paclitaxel, 60Gy in 30#, 50.4Gy in 28#
- Where
- 23 sites in United Kingdom
- Volunteers
- 159 people
- Sponsor
- University of Oxford
Non-Hodgkin's Lymphoma
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease.
- Trial name
- NCT00510471
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine
- Where
- 9 sites in United States
- Sponsor
- Genitope Corporation
Non-small Cell Lung Cancer
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
- Trial name
- CONFIRM (NCT04322578)
- Testing
- Crizotinib, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hunan Province Tumor Hospital
Breast Cancer
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.
- Trial name
- NCT00130533
- Testing
- Capecitabine
- Where
- 48 sites in Spain
- Volunteers
- 876 people
- Sponsor
- Spanish Breast Cancer Research Group
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors treated with targeted…
- Conditions
- Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea
- Trial name
- OnTARGET (NCT04538625)
- Testing
- Crofelemer 125 MG [Mytesi]
- Where
- 52 sites in United States, Argentina and 3 more
- Volunteers
- 287 people
- Sponsor
- Napo Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall…
- Trial name
- NCT02591615
- Testing
- MK-3475, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alliance Foundation Trials, LLC.
Recurrent Ovarian Cancer
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
Effective treatments are desperately needed for ovarian cancer patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to ovarian cancer patients.
- Trial name
- NCT05270720
- Testing
- dendritic cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Second University Hospital
Colonic Cancer, Metastasis
Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6…
- Trial name
- CUFOX (NCT01490996)
- Testing
- Oral complex C3 curcumin + chemotherapy, Chemotherapy only
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Leicester
Non-Small Cell Lung Cancer
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
- Trial name
- NCT02337530
- Testing
- Selumetinib, Pemetrexed, Cisplatin
- Where
- 12 sites in Canada
- Volunteers
- 62 people
- Sponsor
- Canadian Cancer Trials Group
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
- Trial name
- ACTICCA-1 (NCT02170090)
- Testing
- Gemcitabine, Cisplatin, Capecitabine
- Where
- 67 sites in Australia, Austria and 6 more
- Volunteers
- 789 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cancer, Influenza Viral Infections
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
The safety and immunogenicity of high dose influenza vaccine has not been studied in young patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and safety of high dose influenza to standard…
- Trial name
- IMMUNE (NCT01666782)
- Testing
- Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- Saad Jamshed MD
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer
Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's immune system, which in turn may slow the growth of tumors. It is presented in vials as a sterile preparation for IM injection.
- Trial name
- NCT00040092
- Testing
- Virulizin®
- Volunteers
- 400 people
- Sponsor
- Aptose Biosciences Inc.
Pancreas Cancer
A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy
To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one…
- Trial name
- DICI_PC (NCT06172634)
- Testing
- dentritic cell infusion and immunecheckpoint inhibitor
- Volunteers
- 10 people
- Sponsor
- Soonchunhyang University Hospital
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
This study is being done to compare a special type of Positron Emission Tomography (PET) scan with CT scan in patients with surgically removable lung cancer to see which method is more useful in measuring a response to treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT00963807
- Testing
- Cisplatin, CT, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03106077
- Testing
- Mirvetuximab Soravtansine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancers, Triple Negative Breast Cancer (TNBC)
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
OPT-PEMBRO trial is a pragmatic, multicentre, international, prospective, non-inferiority, two-arms, randomised (1:1), open-label, Phase III clinical study.
- Trial name
- OPT-PEMBRO (NCT06606730)
- Testing
- Pembrolizumab, Deescalation
- Where
- 2 sites in Belgium, France
- Volunteers
- 2,454 people
- Sponsor
- UNICANCER
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
This phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT07112053
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington